ATMP classification: the EMA spells out how decisions are made
This article was originally published in RAJ Devices
The European Medicines Agency has adopted a document that explains an optional procedure under which sponsors can request a scientific recommendation from the agency’s Committee for Advanced Therapies in order to establish whether a product should be classified as an advanced therapy medicinal product1.
You may also be interested in...
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.